India, April 17 -- The biotech sector has always been a space where science, capital, and sentiment intersect in complex ways. From cautious optimism around breakthrough therapies to concerns over valuation and funding cycles, analyst perspectives are offering critical signals about where the industry may be headed next.
Wedbush analysts' actions on a few biotech stocks on Thursday are explained below.
Wedbush Reiterates arGEN-X at Outperform, $1000 Price Target
Wedbush analyst David Nierengarten reaffirmed an Outperform rating and a 12-month price target of $1000 for ArGEN-X N.V. (ARGX), a commercial-stage biopharma company developing treatments for autoimmune diseases.
The firm's lead candidate and primary revenue driver is Efgartigim...